J. John Alta Loma Rossi

J. John Alta Loma Rossi's AcademicInfluence.com Rankings

Philosophy

#3683

World Rank

#5903

Historical Rank

Logic

#1328

World Rank

#2050

Historical Rank

philosophy Degrees

Download Badge

Philosophy

J. John Alta Loma Rossi's Degrees

Doctorate Medicine Stanford University

Why Is J. John Alta Loma Rossi Influential?

(Suggest an Edit or Addition)

(See a Problem?)

J. John Alta Loma Rossi's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma (2017) (3053)
The promises and pitfalls of RNA-interference-based therapeutics (2009) (1134)
Unlocking the potential of the human genome with RNA interference (2004) (1123)
Strategies for silencing human disease using RNA interference (2007) (1038)
Aptamers as targeted therapeutics: current potential and challenges (2016) (1023)
Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells (2002) (1001)
Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy (2005) (871)
RNAi therapeutics: principles, prospects and challenges. (2007) (822)
RNA-based therapeutics: current progress and future prospects. (2012) (816)
MicroRNA-directed transcriptional gene silencing in mammalian cells (2008) (723)
MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-β-induced collagen expression via inhibition of E-box repressors (2007) (694)
The current state and future directions of RNAi-based therapeutics (2019) (643)
Ribozymes as potential anti-HIV-1 therapeutic agents. (1990) (611)
Argonaute-1 directs siRNA-mediated transcriptional gene silencing in human cells (2006) (464)
Approaches for the sequence-specific knockdown of mRNA (2003) (448)
Current progress of siRNA/shRNA therapeutics in clinical trials (2011) (439)
Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase (2004) (407)
TGF-β activates Akt kinase via a microRNA-dependent amplifying circuit targeting PTEN (2009) (397)
RNA-Based Gene Therapy for HIV with Lentiviral Vector–Modified CD34+ Cells in Patients Undergoing Transplantation for AIDS-Related Lymphoma (2010) (383)
Effect of fixation on the amplification of nucleic acids from paraffin-embedded material by the polymerase chain reaction. (1991) (382)
Epigenetics and MicroRNAs (2007) (362)
Distance constraints between microRNA target sites dictate efficacy and cooperativity (2007) (349)
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses (2009) (347)
SNPs in human miRNA genes affect biogenesis and function. (2009) (345)
Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. (2008) (309)
Functional polarity is introduced by Dicer processing of short substrate RNAs (2005) (303)
The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells. (2005) (296)
Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC (2007) (281)
RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise? (2016) (276)
Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells (2009) (276)
An Aptamer-siRNA Chimera Suppresses HIV-1 Viral Loads and Protects from Helper CD4+ T Cell Decline in Humanized Mice (2011) (273)
RNAi and small interfering RNAs in human disease therapeutic applications. (2010) (266)
MicroRNAs in disease and potential therapeutic applications. (2007) (254)
Genetic therapies against HIV (2007) (254)
RNAi-based therapeutics–current status, challenges and prospects (2009) (252)
Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. (2005) (251)
De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer (2012) (219)
Approaches for chemically synthesized siRNA and vector‐mediated RNAi (2005) (217)
RNAi mechanisms and applications. (2008) (216)
Synthesis and use of synthetic oligonucleotides. (1984) (213)
Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. (2017) (210)
The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization. (1997) (205)
Metalloproteases regulate T‐cell proliferation and effector function via LAG‐3 (2007) (189)
Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy (2014) (189)
Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. (2018) (186)
Mutations in conserved intron sequences affect multiple steps in the yeast splicing pathway, particularly assembly of the spliceosome. (1986) (185)
Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages. (2003) (181)
siRNA target site secondary structure predictions using local stable substructures (2005) (173)
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges (2013) (172)
Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. (2003) (171)
Elevated glucose and angiotensin II increase 12-lipoxygenase activity and expression in porcine aortic smooth muscle cells. (1993) (168)
Potent siRNA Inhibitors of Ribonucleotide Reductase Subunit RRM2 Reduce Cell Proliferation In vitro and In vivo (2007) (161)
Differential transcription of Pgk genes during spermatogenesis in the mouse. (1992) (161)
Post-transcriptional Up-regulation of Tsc-22 by Ybx1, a Target of miR-216a, Mediates TGF-β-induced Collagen Expression in Kidney Cells*♦ (2010) (160)
Adaptive amphiphilic dendrimer-based nanoassemblies as robust and versatile siRNA delivery systems. (2014) (158)
MicroRNAs in Disease and Potential Therapeutic Applications. (2007) (154)
Cell-specific aptamer-mediated targeted drug delivery. (2011) (153)
Short hairpin RNA-directed cytosine (CpG) methylation of the RASSF1A gene promoter in HeLa cells. (2005) (152)
Functional siRNA expression from transfected PCR products. (2002) (151)
Interaction of musleblind, CUG‐BP1 and hnRNP H proteins in DM1‐associated aberrant IR splicing (2006) (151)
Molecular mechanisms of Dicer: endonuclease and enzymatic activity (2017) (151)
A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. (2009) (145)
Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. (2011) (145)
Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. (1993) (141)
Facilitation of hammerhead ribozyme catalysis by the nucleocapsid protein of HIV‐1 and the heterogeneous nuclear ribonucleoprotein A1. (1994) (138)
Rational design and in vitro and in vivo delivery of Dicer substrate siRNA (2006) (130)
MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors. (2015) (128)
Interplay between HIV-1 infection and host microRNAs (2011) (128)
Aptamer-targeted cell-specific RNA interference (2010) (127)
Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. (1993) (127)
Safety and Efficacy of a Lentiviral Vector Containing Three Anti-HIV Genes-CCR5 Ribozyme, Tat-rev siRNA, and TAR Decoy-in SCID-hu Mouse-Derived T Cells. (2007) (123)
Ribozyme-mediated inhibition of HIV 1 suggests nucleolar trafficking of HIV-1 RNA. (2000) (121)
Direct detection of HIV-1 RNA from AIDS and ARC patient samples. (1988) (120)
Functional In Vivo Delivery of Multiplexed Anti-HIV-1 siRNAs via a Chemically Synthesized Aptamer With a Sticky Bridge (2012) (120)
Cytoplasmic and Nuclear Retained DMPK mRNAs Are Targets for RNA Interference in Myotonic Dystrophy Cells* (2005) (118)
Engineering and optimization of the mir-106b-cluster for ectopic expression of multiplexed anti-HIV RNAs (2008) (118)
Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line (1993) (117)
Current Advances in Aptamers for Cancer Diagnosis and Therapy (2018) (117)
Current Progress of RNA Aptamer-Based Therapeutics (2012) (115)
Combinatorial Latency Reactivation for HIV-1 Subtypes and Variants (2010) (113)
Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. (1994) (111)
The first ATPase domain of the yeast 246-kDa protein is required for in vivo unwinding of the U4/U6 duplex. (1999) (110)
Genome-Wide Profiling Identified a Set of miRNAs that Are Differentially Expressed in Glioblastoma Stem Cells and Normal Neural Stem Cells (2012) (110)
Current status of gene therapy strategies to treat HIV/AIDS. (2005) (110)
Aptamers as targeted therapeutics: current potential and challenges (2017) (107)
CRM1 mediates nuclear-cytoplasmic shuttling of mature microRNAs (2009) (107)
Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes). (1999) (107)
New Hope for a MicroRNA Therapy for Liver Cancer (2009) (106)
A Boost for the Emerging Field of RNA Nanotechnology (2011) (106)
A nucleolar TAR decoy inhibitor of HIV-1 replication (2002) (106)
Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo. (2000) (105)
Chimeric DNA-RNA hammerhead ribozymes have enhanced in vitro catalytic efficiency and increased stability in vivo. (1992) (105)
TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. (2013) (105)
Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo (2014) (102)
A potential role for RNA interference in controlling the activity of the human LINE-1 retrotransposon (2005) (102)
Lentiviral-mediated delivery of siRNAs for antiviral therapy (2006) (101)
Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs. (2008) (101)
Evidence for X-Chromosomal Schizophrenia Associated with microRNA Alterations (2009) (98)
Negative feedback inhibition of HIV-1 by TAT-inducible expression of siRNA (2004) (94)
Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro (2006) (94)
HnRNP H inhibits nuclear export of mRNA containing expanded CUG repeats and a distal branch point sequence (2005) (93)
Antisense-Mediated Inhibition of Human Immunodeficiency Virus (HIV) Replication by Use of an HIV Type 1-Based Vector Results in Severely Attenuated Mutants Incapable of Developing Resistance (2004) (92)
Allogeneic bone marrow transplantation, zidovudine, and human immunodeficiency virus type 1 (HIV-1) infection. Studies in a patient with non-Hodgkin lymphoma. (1989) (92)
RNA accessibility prediction: a theoretical approach is consistent with experimental studies in cell extracts (2000) (89)
Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts. (2003) (89)
Aptamers: Uptake mechanisms and intracellular applications☆ (2018) (89)
Progress and prospects: RNA-based therapies for treatment of HIV infection (2007) (87)
Interaction of MAPK and 12-lipoxygenase pathways in growth and matrix protein expression in mesangial cells. (2002) (85)
Rapid determination and quantitation of the accessibility to native RNAs by antisense oligodeoxynucleotides in murine cell extracts. (1998) (85)
Thermodynamic stability of small hairpin RNAs highly influences the loading process of different mammalian Argonautes (2011) (85)
Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition. (2011) (84)
Piwi-Interacting RNAs (piRNAs) Are Dysregulated in Renal Cell Carcinoma and Associated with Tumor Metastasis and Cancer-Specific Survival (2015) (84)
Small interfering RNAs expressed from a Pol III promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line. (2003) (84)
RNA‐Mediated Inhibition of HIV in a Gene Therapy Setting (2003) (79)
RNAi as a treatment for HIV-1 infection. (2006) (77)
Unexpected point mutations activate cryptic 3' splice sites by perturbing a natural secondary structure within a yeast intron. (1991) (76)
Mastering Dendrimer Self-Assembly for Efficient siRNA Delivery: From Conceptual Design to In Vivo Efficient Gene Silencing. (2016) (75)
Promoting siRNA delivery via enhanced cellular uptake using an arginine-decorated amphiphilic dendrimer. (2015) (74)
Downregulation of the CCR5 beta-chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts. (2000) (74)
Sequence context outside the target region influences the effectiveness of miR-223 target sites in the RhoB 3′UTR (2009) (74)
Control of HIV-1 replication by RNA interference. (2004) (73)
RNA interference approaches for treatment of HIV-1 infection (2015) (73)
RNAi and the P-body connection (2005) (72)
Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells (2013) (71)
Expression strategies for short hairpin RNA interference triggers. (2008) (71)
Regulation of monocyte chemoattractant protein-1 by the oxidized lipid, 13-hydroperoxyoctadecadienoic acid, in vascular smooth muscle cells via nuclear factor-kappa B (NF-kappa B). (2004) (70)
Expressing short hairpin RNAs in vivo (2006) (70)
Plasma Viremia and Cellular HIV-1 DNA Persist Despite Autologous Hematopoietic Stem Cell Transplantation for HIV-Related Lymphoma (2013) (69)
A cytoplasmic pathway for gapmer antisense oligonucleotide-mediated gene silencing in mammalian cells (2015) (69)
Downregulation of TLX induces TET3 expression and inhibits glioblastoma stem cell self-renewal and tumorigenesis (2016) (68)
Dual function transcripts specifying tRNA and mRNA (1981) (67)
Ribozymes as anti-HIV-1 therapeutic agents: principles, applications, and problems. (1992) (67)
Ribozyme-Mediated Inhibition of Rat Leukocyte-Type 12-Lipoxygenase Prevents Intimal Hyperplasia in Balloon-Injured Rat Carotid Arteries (2001) (67)
Inhibition of human immunodeficiency virus by using an oligonucleoside methylphosphonate targeted to the tat-3 gene (1988) (66)
Controlled, targeted, intracellular expression of ribozymes: progress and problems. (1995) (65)
Foamy Combinatorial Anti-HIV Vectors with MGMTP140K Potently Inhibit HIV-1 and SHIV Replication and Mediate Selection In Vivo (2009) (65)
Protection of Stem Cell-Derived Lymphocytes in a Primate AIDS Gene Therapy Model after In Vivo Selection (2009) (65)
Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity. (2015) (65)
Selection strategy to generate aptamer pairs that bind to distinct sites on protein targets. (2012) (64)
Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer (2017) (64)
Novel Pol II Fusion Promoter Directs Human Immunodeficiency Virus Type 1-Inducible Coexpression of a Short Hairpin RNA and Protein (2006) (63)
Localized expression of small RNA inhibitors in human cells. (2003) (63)
Aptamer-Based Therapeutics: New Approaches to Combat Human Viral Diseases (2013) (63)
siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS. (2003) (62)
Ribozymes, genomics and therapeutics. (1999) (62)
A role for the Dicer helicase domain in the processing of thermodynamically unstable hairpin RNAs (2008) (62)
RNA enzymes (ribozymes) as antiviral therapeutic agents. (1990) (61)
Kluyveromyces lactis maintains Saccharomyces cerevisiae intron-encoded splicing signals (1989) (61)
Adenoviral Delivery of a Leukocyte-Type 12 Lipoxygenase Ribozyme Inhibits Effects of Glucose and Platelet-Derived Growth Factor in Vascular Endothelial and Smooth Muscle Cells (2001) (59)
Molecular basis for improved gene silencing by Dicer substrate interfering RNA compared with other siRNA variants (2013) (59)
RNA-Based TWIST1 Inhibition via Dendrimer Complex to Reduce Breast Cancer Cell Metastasis (2015) (58)
Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth (2016) (58)
Expression of long anti-HIV-1 hairpin RNAs for the generation of multiple siRNAs: advantages and limitations. (2008) (58)
A role for human Dicer in pre-RISC loading of siRNAs (2010) (57)
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial (2020) (56)
Amplification of RNAi--targeting HLA mRNAs. (2005) (55)
Toxicity in mice expressing short hairpin RNAs gives new insight into RNAi (2006) (55)
A facile lentiviral vector system for expression of doxycycline-inducible shRNAs: knockdown of the pre-miRNA processing enzyme Drosha. (2007) (54)
Evidence that a leukocyte type of 12-lipoxygenase is expressed and regulated by angiotensin II in human adrenal glomerulosa cells. (1994) (54)
Isolation and functional analysis of a Kluyveromyces lactis RAP1 homologue. (1994) (53)
Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo (2016) (53)
Lentivirus-mediated RNA interference therapy for human immunodeficiency virus type 1 infection. (2006) (53)
RNAi in Combination with a Ribozyme and TAR Decoy for Treatment of HIV Infection in Hematopoietic Cell Gene Therapy (2006) (51)
Gene activation of CEBPA using saRNA: Preclinical studies of the first in human saRNA drug candidate for liver cancer (2018) (51)
High throughput sequencing analysis of RNA libraries reveals the influences of initial library and PCR methods on SELEX efficiency (2016) (51)
Survival of the Fittest: Positive Selection of CD4+ T Cells Expressing a Membrane-Bound Fusion Inhibitor Following HIV-1 Infection (2010) (50)
Lentiviral vector delivery of siRNA and shRNA encoding genes into cultured and primary hematopoietic cells. (2005) (50)
An alternate method for synthesis of double-stranded DNA segments. (1982) (49)
Ribozyme-mediated RNA degradation in nuclei suspension. (1995) (49)
AptaTRACE Elucidates RNA Sequence-Structure Motifs from Selection Trends in HT-SELEX Experiments. (2016) (48)
Regulation of host gene expression by HIV-1 TAR microRNAs (2013) (48)
Principles of Dicer substrate (D-siRNA) design and function. (2008) (48)
Mammalian Dicer finds a partner (2005) (47)
RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model. (2002) (47)
A bias-reducing strategy in profiling small RNAs using Solexa. (2011) (47)
The tyrT locus: Termination and processing of a complex transcript (1981) (47)
5′ Unlocked Nucleic Acid Modification Improves siRNA Targeting (2013) (47)
Ribozyme therapy for HIV infection. (2000) (47)
Durability of transgene expression and vector integration: recombinant SV40-derived gene therapy vectors. (2002) (45)
Development of Hematopoietic Stem Cell Based Gene Therapy for HIV-1 Infection: Considerations for Proof of Concept Studies and Translation to Standard Medical Practice (2013) (45)
Creating genetic resistance to HIV. (2012) (45)
Sensing the danger in RNA (2005) (45)
Optimization and characterization of tRNA-shRNA expression constructs (2007) (45)
Rev-binding aptamer and CMV promoter act as decoys to inhibit HIV replication. (2000) (45)
Yeast pre‐messenger RNA splicing efficiency depends on critical spacing requirements between the branch point and 3′ splice site. (1986) (44)
Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy. (2001) (44)
Hematopoietic cell transplantation with cord blood for cure of HIV infections. (2013) (44)
RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics. (2012) (43)
Small Nuclear RNAs Encoded by Herpesvirus saimiri Upregulate the Expression of Genes Linked to T Cell Activation in Virally Transformed T Cells (2005) (43)
The therapeutic potential of cell-internalizing aptamers. (2009) (43)
Endogenous Expression of an Anti-TAR Aptamer Reduces HIV-1 Replication (2006) (43)
Identification and characterization of yeast mutants that overcome an experimentally introduced block to splicing at the 3' splice site. (1996) (42)
Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T-cell therapy. (2020) (42)
Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19). (2017) (41)
Saccharomyces cerevisiae actin--Escherichia coli lacZ gene fusions: synthetic-oligonucleotide-mediated deletion of the 309 base pair intervening sequence in the actin gene. (1983) (41)
Lentiviral vector delivery of siRNA and shRNA encoding genes into cultured and primary hematopoietic cells. (2008) (41)
Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape. (2013) (41)
Short hairpin RNA causes the methylation of transforming growth factor-beta receptor II promoter and silencing of the target gene in rat hepatic stellate cells. (2007) (41)
Current progress in the development of RNAi-based therapeutics for HIV-1 (2011) (41)
Ribozyme-mediated inhibition of expression of leukocyte-type 12-lipoxygenase in porcine aortic vascular smooth muscle cells. (1995) (40)
Structure and organization of the two tRNATyr gene clusters on the E. coli chromosome (1979) (40)
The potential use of catalytic RNAs in therapy of HIV infection and other diseases. (1991) (38)
Lentiviral vector delivery of recombinant small interfering RNA expression cassettes. (2005) (38)
Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery. (2011) (38)
Use of polymerase chain reaction to detect the expression of the Mr 70,000 heat shock genes in control or heat shock leukemic cells as correlated to their heat response. (1990) (38)
Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5 (2004) (38)
The role of antisense long noncoding RNA in small RNA-triggered gene activation (2014) (38)
Aptamer-targeted RNAi for HIV-1 therapy. (2011) (38)
MicroRNAs and their potential involvement in HIV infection. (2011) (37)
Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1 (2018) (37)
ENHANCED INHIBITION OF HIV-1 REPLICATION IN MACROPHAGES BY ANTISENSE OLIGONUCLEOTIDES, RIBOZYMES AND ACYCLIC NUCLEOSIDE PHOSPHONATE ANALOGS DELIVERED IN pH-SENSITIVE LIPOSOMES (2001) (37)
RNAi therapeutics: SNALPing siRNAs in vivo (2006) (37)
Coupling of RNAi-mediated target downregulation with gene replacement. (2003) (37)
Proline Excretion and Indirect Suppression in Escherichia coli and Salmonella typhimurium (1974) (36)
Progress in RNAi-based antiviral therapeutics. (2011) (36)
Antisense catalytic RNAs as therapeutic agents. (1994) (36)
Rapid assessment of anti-HIV siRNA efficacy using PCR-derived Pol III shRNA cassettes. (2004) (36)
The application of ribozymes to HIV infection. (1999) (36)
Detection of antisense and ribozyme accessible sites on native mRNAs: application to NCOA3 mRNA. (2001) (35)
Specific killing of Ph+ chronic myeloid leukemia cells by a lentiviral vector-delivered anti-bcr/abl small hairpin RNA. (2003) (35)
mRNA localization signals can enhance the intracellular effectiveness of hammerhead ribozymes. (1999) (35)
Anti-HIV-1 gene expressing lentiviral vectors as an adjunctive therapy for HIV-1 infection. (2004) (34)
Liver Activation of Hepatocellular Nuclear Factor-4α by Small Activating RNA Rescues Dyslipidemia and Improves Metabolic Profile (2019) (34)
Intracellular ribozyme applications. (2001) (34)
Chemical modifications rescue off-target effects of RNAi. (2006) (34)
Uncoupling of RNAi from active translation in mammalian cells. (2005) (34)
An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFRα Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma (2018) (33)
Biological expression of an Escherichia coli consensus sequence promoter and some mutant derivatives. (1983) (33)
The anti-miR21 antagomir, a therapeutic tool for colorectal cancer, has a potential synergistic effect by perturbing an angiogenesis-associated miR30 (2014) (32)
A nucleolar localizing Rev binding element inhibits HIV replication (2006) (31)
Therapeutic Potential of Aptamer-siRNA Conjugates for Treatment of HIV-1 (2012) (31)
Gene therapy: a bold direction for HIV-1 treatment. (1993) (31)
Lentiviral transduction of Tar Decoy and CCR5 ribozyme into CD34+ progenitor cells and derivation of HIV-1 resistant T cells and macrophages (2004) (31)
Expression of hammerhead ribozymes by retroviral vectors to inhibit HIV-1 replication: comparison of RNA levels and viral inhibition. (1996) (31)
HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy (2018) (31)
Delivery of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes. (1998) (30)
Oligonucleotide scanning of native mRNAs in extracts predicts intracellular ribozyme efficiency: ribozyme-mediated reduction of the murine DNA methyltransferase. (2000) (29)
Gene Expression Profile Changes After Short-activating RNA-mediated Induction of Endogenous Pluripotency Factors in Human Mesenchymal Stem Cells (2012) (29)
Aptamer-siRNA chimeras for HIV. (2015) (29)
Targeted Molecular Imaging Using Aptamers in Cancer (2018) (29)
Partial purification and some properties of delta1-pyrroline-5-carboxylate reductase from Escherichia coli (1977) (29)
Antiviral Applications of RNAi (2006) (28)
Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL). (2017) (28)
Use of a U16 snoRNA-containing ribozyme library to identify ribozyme targets in HIV-1. (2008) (28)
Biogenesis and function of endogenous and exogenous siRNAs (2010) (28)
A test for intron function in the yeast actin gene (1985) (28)
Receptor ligand-facilitated cationic liposome delivery of anti-HIV-1 Rev-binding aptamer and ribozyme DNAs. (1998) (27)
Cross-Clade Inhibition of Recombinant Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus SIVcpz Reverse Transcriptases by RNA Pseudoknot Aptamers (2007) (27)
Ex vivo gene therapy for HIV-1 treatment. (2011) (27)
Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma (2018) (27)
Typical and atypical trafficking pathways of Ad5 penton base recombinant protein: implications for gene transfer (2006) (27)
Persistence of bcr-able gene expression following bone marrow transplantation for chronic myelogenous leukemia in chronic phase. (1991) (27)
Catalytic antisense RNA (ribozymes): their potential and use as anti-HIV-1 therapeutic agents. (1992) (27)
TLR agonist–Stat3 siRNA conjugates: cell-specific gene silencing and enhanced antitumor immune responses (2009) (27)
Bcl-2 Protein in 518A2 Melanoma Cells In vivo and In vitro (2006) (26)
Therapeutic antisense and ribozymes. (1995) (26)
RNAi applications in mammalian cells. (2004) (25)
Arginine side-chain dynamics in the HIV-1 rev-RRE complex. (2000) (25)
Gene transfer : delivery and expression of DNA and RNA : a laboratory manual (2007) (24)
Medicine: A cholesterol connection in RNAi (2004) (24)
Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene. (1997) (24)
Optimized Lentiviral Vectors for HIV Gene Therapy: Multiplexed Expression of Small RNAs and Inclusion of MGMTP140K Drug Resistance Gene (2014) (23)
Activation of a cryptic TACTAAC box in the Saccharomyces cerevisiae actin intron (1986) (23)
Emerging cancer-specific therapeutic aptamers (2017) (23)
Overview of Gene Silencing by RNA Interference (2009) (23)
Mechanisms involved in the activation of C/EBPα by small activating RNA in hepatocellular carcinoma (2019) (22)
Comparative single‐turnover kinetic analyses of trans‐cleaving hammerhead ribozymes with naturally derived non‐conserved sequence motifs (2005) (22)
Endogenous MCM7 microRNA cluster as a novel platform to multiplex small interfering and nucleolar RNAs for combinational HIV-1 gene therapy. (2012) (22)
Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer (2021) (22)
Dual Mechanisms of Action of Self-Delivering, Anti-HIV-1 FANA Oligonucleotides as a Potential New Approach to HIV Therapy (2019) (22)
Intracellular applications of ribozymes. (2001) (22)
Oligonucleotides and the COVID-19 Pandemic: A Perspective. (2020) (21)
Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma (2013) (21)
Small interfering RNAs to the rescue: blocking L1 retrotransposition (2006) (21)
Therapeutic Potential of small Activating RNAs (saRNAs) in Human Cancers (2018) (21)
Recent applications of RNAi in mammalian systems. (2004) (21)
Editorial: Introductory Remarks on the General Application of Antisense RNAs and Ribozymes (1993) (21)
Monitoring Retroviral RNA Dimerization In Vivo via Hammerhead Ribozyme Cleavage (1998) (21)
Dual-targeting siRNAs. (2010) (21)
Anti-HIV therapy with antisense oligonucleotides and ribozymes: realistic approaches or expensive myths? (1996) (20)
Blind SELEX Approach Identifies RNA Aptamers That Regulate EMT and Inhibit Metastasis (2017) (20)
Combinatorial RNA-based gene therapy for the treatment of HIV/AIDS (2013) (20)
Correlation of activity with stability of chemically modified ribozymes in nuclei suspension. (1996) (19)
Differential Recovery of Auxotrophs After Penicillin Enrichment in Escherichia coli (1971) (19)
Incorporation of aptamers in the terminal loop of shRNAs yields an effective and novel combinatorial targeting strategy (2017) (19)
Biological and functional aspects of catalytic RNAs. (1992) (19)
siRNA Drugs: Here to Stay. (2021) (19)
Effect of Enrichment Procedure upon Auxotroph Recovery in Escherichia coli K-12 (1975) (19)
Enhanced expression and HIV-1 inhibition of chimeric tRNA(Lys3)-ribozymes under dual U6 snRNA and tRNA promoters. (2002) (18)
Hammerhead ribozyme-mediated cleavage of the human insulin-like growth factor-II ribonucleic acid in vitro and in prostate cancer cells. (1999) (18)
Cell-Type–Specific Aptamer and Aptamer-Small Interfering RNA Conjugates for Targeted Human Immunodeficiency Virus Type 1 Therapy (2014) (18)
Abstract CT019: Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL) (2017) (18)
In vivo, high-resolution analysis of yeast and mammalian RNA-protein interactions, RNA structure, RNA splicing and ribozyme cleavage by use of terminal transferase-dependent PCR. (2000) (18)
Practical Ribozymes: Making ribozymes work in cells (1994) (18)
Transcriptional activation by small RNA duplexes. (2007) (17)
Anti-CD19 chimeric antigen receptor T cells preceded by low-dose chemotherapy to induce remissions of advanced lymphoma. (2016) (17)
Intracellular ribozyme applications: principles and protocols. (1999) (17)
Altered response to growth rate changes in Kluyveromyces lactis versus Saccharomyces cerevisiae as demonstrated by heterologous expression of ribosomal protein 59 (CRY1) (1991) (17)
Anti-HIV Therapeutic Hammerhead Ribozymes: Targeting Strategies and Optimization of Intracellular Function (1996) (17)
Ribozyme-mediated cleavage of an HIV-1 gag RNA: the effects of nontargeted sequences and secondary structure on ribozyme cleavage activity. (1991) (17)
Ribozymes in the Nucleolus (1999) (17)
Intracellular expression and function of antisense catalytic RNAs. (2000) (17)
Transcriptional gene silencing using small RNAs. (2009) (16)
Delivery of novel macromolecular drugs against HIV-1 (2001) (16)
Targeted Delivery of C/EBPα-saRNA by RNA Aptamers Shows Anti-tumor Effects in a Mouse Model of Advanced PDAC (2019) (16)
Ribozymes to the rescue: repairing genetically defective mRNAs. (1998) (16)
Structural organization of Escherichia coli tRNAtyr gene clusters in four different transducing bacteriophages. (1979) (16)
A chimeric tRNA(Lys3)-ribozyme inhibits HIV replication following virion assembly. (1995) (16)
Ribozymes as Therapies for AIDS a (1990) (15)
Virion encapsidation of tRNA(3Lys)-ribozyme chimeric RNAs inhibits HIV infection. (1998) (15)
Therapeutic applications of catalytic antisense RNAs (ribozymes). (1997) (15)
Small interfering RNAs targeting cyclin D1 and cyclin D2 enhance the cytotoxicity of chemotherapeutic agents in mantle cell lymphoma cell lines (2011) (15)
Problems associated with reporter assays in RNAi studies (2009) (15)
Current progress and challenges in HIV gene therapy. (2011) (15)
Innate Immunity confounds the clinical efficacy of small interfering RNAs (siRNAs) (2009) (15)
PCR-based quantitation of low levels of HIV-1 DNA by using an external standard. (1992) (15)
Inhibition of infectious human immunodeficiency virus type 1 virions via lentiviral vector encoded short antisense RNAs. (2006) (15)
Phylogenetic Comparison of Small RNA-triggered Transcriptional Gene Silencing* (2011) (15)
Synthesis and use of an amphiphilic dendrimer for siRNA delivery into primary immune cells (2020) (15)
Strategies in designing multigene expression units to downregulate HIV-1. (2010) (15)
MicroRNA-181a* Targets Nanog in a Subpopulation of CD34+ Cells Isolated From Peripheral Blood (2012) (15)
Monocytoid B-cell lymphoma in a patient with human immunodeficiency virus infection. Demonstration of human immunodeficiency virus sequences in paraffin-embedded lymph node sections by polymerase chain reaction amplification. (1990) (14)
Ribozymes: use as anti-HIV therapeutic molecules. (1993) (14)
Status of Ribozyme and Antisense‐Based Developmental Approaches for Anti‐HIV‐1 Therapy a (1992) (14)
Safety and efficacy of a lentiviral vector containing three anti-HIV genes--CCR5 ribozyme, tat-rev siRNA, and TAR decoy--in SCID-hu mouse-derived T cells. (2007) (14)
Progress toward curing HIV infection with hematopoietic cell transplantation (2015) (14)
Cloning and detecting signature microRNAs from mammalian cells. (2007) (14)
A Novel Class of HIV-1 Antiviral Agents Targeting HIV via a SUMOylation-Dependent Mechanism (2015) (13)
A novel nuclear miRNA mediated modulation of a non‐coding antisense RNA and its cognate sense coding mRNA (2011) (13)
Receptor-targeted siRNAs (2005) (13)
Meeting Report. Ribozymes: progress and prospects of catalytic RNA as therapeutic agents. (1991) (13)
Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL). (2017) (13)
Ribozyme cleavage leads to decreased expression of fibroblast growth factor receptor 3 in human multiple myeloma cells, which is associated with apoptosis and downregulation of vascular endothelial growth factor. (2005) (13)
Construction and transfection of PCR products expressing siRNAs or shRNAs in mammalian cells. (2004) (13)
Deep Sequencing Analyses of DsiRNAs Reveal the Influence of 3′ Terminal Overhangs on Dicing Polarity, Strand Selectivity, and RNA Editing of siRNAs (2012) (13)
Optimized Lentiviral Vectors for HIV Gene Therapy: Multiplexed Expression of Small RNAs and Inclusion of MGMTP140K Drug Resistance Gene. (2014) (12)
Isolation of a mouse pseudo tRNA gene encoding CCA—a possible example of reverse flow of genetic information (1982) (12)
Exploiting Human CD34+ Stem Cell–conditioned Medium for Tissue Repair (2013) (12)
Rational design of micro-RNA-like bifunctional siRNAs targeting HIV and the HIV coreceptor CCR5. (2010) (12)
HIV-1 RRE RNA acts as an RNA silencing suppressor by competing with TRBP-bound siRNAs (2015) (12)
SiRNA Delivery Methods (2016) (12)
Functional colocalization of ribozymes and target mRNAs in Drosophila oocytes (2001) (11)
Therapeutic applications of RNA interference: recent advances in siRNA design. (2004) (11)
A dual function TAR Decoy serves as an anti-HIV siRNA delivery vehicle (2010) (11)
Cell Cycle Abnormalities Associated with Differential Perturbations of the Human U5 snRNP Associated U5-200kD RNA Helicase (2013) (11)
Silencing of endogenous envelope genes in human choriocarcinoma cells shows that envPb1 is involved in heterotypic cell fusions. (2012) (10)
Ribozymes expressed within the loop of a natural antisense RNA form functional transcription terminators. (1995) (10)
Regulation of Gene Expression by Small RNAs (2009) (10)
Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice (2019) (10)
A Short-activating RNA Oligonucleotide Targeting the Islet β-cell Transcriptional Factor MafA in CD34+ Cells. (2013) (10)
Use of a hammerhead ribozyme with cationic liposomes to reduce leukocyte type 12-lipoxygenase expression in vascular smooth muscle. (1997) (10)
Structural similarities between hammerhead ribozymes and the spliceosomal RNAs could be responsible for lack of ribozyme cleavage in yeast. (1998) (10)
Ribozymes: principles and designs for their use as antisense and therapeutic agents (1992) (10)
Wandering eye for RNAi. (2008) (9)
Zuma-6: Phase 1-2 multicenter study evaluating safety and efficacy of axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab in patients with refractory diffuse large b-cell lymphoma (DLBCL). (2017) (9)
Bivalent aptamers deliver the punch. (2008) (9)
RNA nanoparticles come of age. (2011) (9)
Exploring the use of antisense, enzymatic RNA molecules (ribozymes) as therapeutic agents. (1991) (9)
Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation (2018) (9)
Silencing of Gene Expression in Cultured Cells Using Small Interfering RNAs (2010) (9)
Preclinical Assessment of Mutant Human TRIM5α as an Anti-HIV-1 Transgene. (2015) (9)
Expression of the human immunodeficiency virus type 1 primer binding sequence inhibits HIV-1 replication. (1998) (8)
Methods for assembling B-cell lymphoma specific and internalizing aptamer-siRNA nanoparticles via the sticky bridge. (2015) (8)
Effect of 2′-5′/3′-5′ phosphodiester linkage heterogeneity on RNA interference (2020) (8)
Functional and intracellular localization properties of U6 promoter-expressed siRNAs, shRNAs, and chimeric VA1 shRNAs in mammalian cells. (2008) (8)
Advanced Cell Mapping Visualizations for Single Cell Functional Proteomics Enabling Patient Stratification (2020) (8)
Abstract CT020: Immune signatures of cytokine release syndrome and neurologic events in a multicenter registrational trial (ZUMA-1) in subjects with refractory diffuse large B cell lymphoma treated with axicabtagene ciloleucel (KTE-C19) (2017) (8)
Therapeutic ribozymes: principles and applications. (1998) (8)
Exogenous cellular delivery of ribozymes and ribozyme encoding DNAs. (1997) (8)
Future strategies for the discovery of therapeutic aptamers (2017) (7)
Lentivirus transduction of hematopoietic cells. (2007) (7)
The development of RNA interference therapeutics. (2011) (7)
Functional expression of a yeast ochre suppressor tRNA gene in Escherichia coli. (1982) (7)
Autologous Stem Cell Transplantation (ASCT) for AIDS-Related Lymphomas (ARL) and the Potential Role of HIV-Resistant Stem Cells. (2006) (7)
Combinatorial RNA‐based Therapies for HIV‐1 (2008) (7)
Treatment of Pancreatic Cancer by Aptamer Conjugated C/EBPα-saRNA. (2017) (7)
Erratum: Wandering eye for RNAi (2008) (7)
Stem cells, ribozymes and HIV (2009) (7)
Molecular medicine: Entry granted (2007) (7)
Recent applications of RNA interference (RNAi) in mammalian systems (2003) (6)
Cooperative interaction of branch signals in the actin intron of Saccharomyces cerevisiae. (1998) (6)
Cholesterol paves the way for topically applied viricides. (2009) (6)
Uncovering Differently Expressed Markers and Heterogeneity on Human Pancreatic Cancer (2020) (6)
Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies. (2019) (6)
Novel ribozyme, RNA decoy, and siRNA approaches to inhibition of HIV in a gene therapy setting (2003) (6)
Design of Effective Primary MicroRNA Mimics With Different Basal Stem Conformations (2016) (6)
Enhancement of ribozyme function by RNA binding proteins. (1997) (6)
Targeted cleavage: Tuneable cis-cleaving ribozymes (2007) (6)
The diversity of RNAi and its applications. (2006) (6)
MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models (2021) (6)
Resurrecting DNAzymes as Sequence-Specific Therapeutics (2012) (5)
Noncoding oligonucleotides: the belle of the ball in gene therapy. (2015) (5)
Product characteristics associated with in vivo expansion of anti-CD19 CAR T cells in patients treated with axicabtagene ciloleucel (axi-cel). (2017) (5)
Chitosan Oleate Coated PLGA Nanoparticles as siRNA Drug Delivery System (2021) (5)
Helping RNAi deliver. (2005) (5)
Enhancing siRNA effects in T cells for adoptive immunotherapy (2005) (5)
First in Human Engraftment of Anti-HIV Lentiviral Vector Gene Modified CD34+ Peripheral Blood Progenitor Cells in the Treatment of AIDS Related Lymphoma (ARL). (2008) (5)
Nucleolar Localization of HIV-1 Rev Is Required, Yet Insufficient for Production of Infectious Viral Particles (2018) (5)
Ribozyme diagnostics comes of age. (2004) (5)
MicroRNA-181a* Targets Nanog in a Subpopulation of CD34+ Cells Isolated From Peripheral Blood. (2012) (4)
Allogeneic Bone Marrow Transplantation, Zidovudine, and Human Immunodeficiency Virus Type 1 (HIV-I) Infection (2020) (4)
Publisher Correction: The current state and future directions of RNAi-based therapeutics (2019) (4)
Partnering aptamer and RNAi technologies. (2006) (4)
Regulation of host gene expression by HIV-1 TAR microRNAs (2013) (4)
Role of the Nucleolus in HIV Infection and Therapy (2011) (4)
Retroviral delivery and anti-HIV testing of hammerhead ribozymes. (1997) (4)
A Short-activating RNA Oligonucleotide Targeting the Islet β-cell Transcriptional Factor MafA in CD34+ Cells (2013) (4)
CRED9: a differentially expressed elncRNA regulates expression of transcription factor CEBPA (2021) (4)
Topical antiviral siRNA: A practical siRNA microbicide? (2006) (4)
Abstract 2990: Polyfunctional anti-CD19 CAR T cells determined by single-cell multiplex proteomics associated with clinical activity in patients with advanced non-Hodgkin’s lymphoma (2017) (4)
Correlation between miRNA (miR) and gene expression profiles (GEP) and response to neoadjuvant chemotherapy (NT) in patients with locally advanced and inflammatory breast cancer (BC). (2011) (4)
Triplex Hybridization of siRNA with Bifacial Glycopolymer Nucleic Acid Enables Hepatocyte-Targeted Silencing. (2019) (4)
Therapeutic Ribozymes (2012) (4)
Small sequence insertions within the branch point region dictate alternative sites of lariat formation in a yeast intron. (1992) (4)
Identification of Nucleolar Factors During HIV-1 Replication Through Rev Immunoprecipitation and Mass Spectrometry. (2019) (4)
Confirmation of HIV infection using gene amplification. (1989) (3)
Mechanisms and Barriers to RNAi Delivery (2013) (3)
Designing and Testing of Ribozymes as Therapeutic Agents (1993) (3)
Chapter 14:RNA Based Therapies for Treatment of HIV Infection (2008) (3)
Tat-regulated expression of RNA interference: Triggers for the treatment of HIV infection (2008) (3)
Tissue-Specific Delivery of Oligonucleotides. (2019) (3)
PERSISTENCE OF bcr‐abl GENE EXPRESSION FOLLOWING BONE MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE (1991) (3)
Proline excretion in Escherichia coli: A comparison of an argD+ strain and a proline-excreting argD− derivative (1977) (3)
Promoting Gene Therapy: Expression Systems for Iransgenes and Post-transcriptional Gene Silencing (2006) (3)
In vivo detection of ribozyme cleavage products and RNA structure by use of terminal transferase-dependent PCR. (2004) (3)
Stopping RNA interference at the seed (2011) (3)
An inexpensive membrane filtration manifold. (1975) (3)
324: The Feasibility of using CCR5Δ32/Δ32 Hematopoietic Stem Cell Transplants for Immune Reconstitution in HIV-Infected Children (2008) (3)
Unusual interactions between cleavage products of a cis-cleaving hammerhead ribozyme. (1998) (2)
A critical assessment of the potential of short interfering RNA therapeutics. (2005) (2)
Inducible and reversible breaching of the blood brain barrier by RNAi (2011) (2)
Cancer Therapeutic Applications of Ribozymes and RNAi (2005) (2)
RNA preparations from yeast cells (1996) (2)
KTE-C19, an Anti-CD19 Chimeric Antigen an Anti-CD19 Chimeric Antigen Receptor (CAR) T cell Therapy in Adult Patients (Pts) With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the ZUMA-3 Trial: Preliminary Results of Novel Safety Interventions (2017) (2)
AptaTRACE: Elucidating Sequence-Structure Binding Motifs by Uncovering Selection Trends in HT-SELEX Experiments (2016) (2)
Alteration of branch site consensus sequence and enhanced pre-mRNA splicing of an NMDAR1 intron not associated with schizophrenia. (2002) (2)
The effect of Dicer knockout on RNA interference using various Dicer substrate interfering RNA structures (2020) (2)
A Multifunctional LNA Oligonucleotide-Based Strategy Blocks AR Expression and Transactivation Activity in PCa Cells (2020) (2)
Ongoing complete remissions (CR) in the phase 1 of ZUMA-1: a phase 1-2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive B-cell Non-Hodgkin Lymphoma (NHL). (2016) (2)
Author Correction: The current state and future directions of RNAi-based therapeutics (2019) (2)
Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL): Long-Term Follow-up of the Pivotal Zuma-1 Trial (2018) (2)
Realizing the promise of RNAi. (2008) (2)
SiRNA delivery methods : methods and protocols (2016) (2)
TREATMENT OF AIDS LYMPHOMA WITH HIGH‐DOSE CHEMOTHERAPY AND GENETICALLY MODIFIED STEM CELLS: A MODEL FOR EVALUATION OF GENE THERAPY.: ABSTRACT S19 (2000) (2)
Dotting the I's and crossing the T's: integration analyses in transduced patient T cells. (2009) (2)
Programmable siRNA pro-drugs that activate RNAi activity in response to specific cellular RNA biomarkers (2022) (2)
Irradiated compared with nonirradiated NSG mice for the development of a human B-cell lymphoma model. (2014) (2)
Evolution of Cell-Type-Specific RNA Aptamers Via Live Cell-Based SELEX. (2016) (2)
Methods in Molecular Medicine, 11: Therapeutic Applications of Ribozymes (1998) (2)
RNA Nanotechnology Approach for Targeted Delivery of RNA Therapeutics Using Cell-Internalizing Aptamers (2013) (2)
Current Progress and Future Prospects in Nucleic Acid Based Therapeutics (2017) (2)
Systemic administration of a novel development candidate, MTL-CEBPA, up-regulates the liver-enriched transcription factor C/EBP-α and reverses CCl4-induced liver failure in vivo (2015) (2)
Nucleic Acid Modification Improves siRNA Targeting (2013) (2)
siRNA Delivery: Mastering Dendrimer Self-Assembly for Efficient siRNA Delivery: From Conceptual Design to In Vivo Efficient Gene Silencing (Small 27/2016). (2016) (2)
Enhancing SIRT1 Gene Expression Using Small Activating RNAs: A Novel Approach for Reversing Metabolic Syndrome. (2022) (2)
Self‐Cleaving RNAs (Ribozymes) as New Modalities for Anti‐HIV Therapy (1990) (2)
Use of a hammerhead ribozyme with cationic liposomes to reduce leukocyte type 12-lipoxygenase expression in vascular smooth muscle (2004) (1)
Oligonucleotide therapeutics : Fourth annual meeting (2009) (1)
In Defense of Antisense (2001) (1)
133 Aptamer-siRNA Chimera Therapy Suppresses HIV-1 Viral Loads and Protects from CD4 T-Cell Loss in Humanized (RAG-hu) Mice (2011) (1)
Lymphoma Cells in Patients Undergoing Transplantation for AIDS-Related + Modified CD 34 − RNA-Based Gene Therapy for HIV with Lentiviral Vector (2010) (1)
Escherichia coli tRNA Tyr Gene Clusters: Organization and Structure (1980) (1)
Aptamer-Mediated siRNA Targeting (2013) (1)
Capture, mutate, quantitate: variations of a central PCR scheme. (1992) (1)
Procedure for Isolating Mutants Defective in Metabolite Transport or Utilization (1975) (1)
Enzymatic synthesis of oligoribonucleotides of defined sequence. (1987) (1)
Nucleic Acid‐Based Therapies (2010) (1)
RAFTing Towards the Shore of Nanotherapeutic. (2018) (1)
Novel Cell type-specific aptamer-siRNA delivery system for HIV-1 therapy (2007) (1)
8. Potent Inhibition of HIV-1 Replication by Lentiviral Vectors Carrying Anti-Vif siRNA (2005) (1)
Abstract 3856: MTLCEBPA, a drug candidate for hepatocellular-carcinoma enhances efficacy of Sorafenib (2019) (1)
671. Potent Anti-Tumor Effects of ApDCs (Aptamer Drug Conjugates) for Targeted Therapeutics in Pancreatic Cancer (2016) (1)
Screening effective target sites on mRNA: a ribozyme library approach. (2012) (1)
RNAi impacts the world of antisense (2003) (1)
Cationic liposome-mediated delivery of anti-HIV-1 ribozyme to chronically infected cells (1995) (1)
Primate in utero gene transfer comes of age. (2001) (1)
Abstract 1730: Up-regulation of C/EBPα inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and cancer patients (2021) (1)
OTS highlights advance in basic and translational aspects of oligonucleotide research. (2011) (1)
Substitution of non-catalytic stem and loop regions of hammerhead ribozyme with DNA counterparts only increases KM without sacrificing the catalytic step (kcat): a way to improve substrate-specificity. (1992) (1)
Hematopoietic Cell Therapy for Human Immunodeficiency Virus Infection (2016) (1)
367. Development of Lentiviral Vectors Carrying shRNA, Ribozyme and RNA Decoy for the Inhibition of HIV-1 Infection (2004) (1)
THE ROLE OF SYNTHETIC DNA IN THE PREPARATION OF STRUCTURAL GENES CODING FOR PROTEINS (1982) (1)
Antiviral Evaluation of HIV-1 Specific Ribozyme Expressed in CD4+ HeLa Cells (1991) (1)
The Potential and Current Progress of Internalizing Molecules in Targeted Drug Delivery (2011) (1)
Abstract 3211: MTL-CEBPA combined with radiofrequency ablation and immunotherapy enhances immunological anti-tumour response in an HCC mouse model (2019) (1)
810. Comparison of Anti-HIV Activity from Various Lentiviral Vectors Carrying Anti-HIV shRNA In Vitro (2006) (1)
Abstract LB-247: 5′-tRFHis-GTG, a novel tRNA-derived novel miRNA-like small non-coding RNA, aberrantly expressed in metastatic renal cell carcinoma by promoting tumor cell proliferation, migration and invasion. (2013) (1)
Designing and utilization of siRNAs targeting RNA binding proteins. (2008) (1)
KTE-C19 (anti-CD19 chimeric antigen receptor [CAR] T cell therapy) in pediatric and adolescent patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL): Preliminary Results of ZUMA-4 (2017) (1)
RNA VIRUS VECTORS II (2006) (1)
Hepatocellular Nuclear Factor 4 alpha (HNF-4 alpha) activation by saRNA rescues dyslipidemia and promotes favorable metabolic profile in a high fat diet (HFD) fed rat model. (2016) (1)
Therapeutic Applications of Ribozymes (2004) (1)
RNA interference as a potential antiviral (2006) (0)
Interim Analysis of a Phase 2 Study of Bortezomib Plus Rituximab Maintenance Therapy in Patients with Mantle Cell Lymphoma Status Post Autologous Stem Cell Transplantation (2015) (0)
The Bi-Functional RNA Aptamers Inhibit Pancreatic Ductal Adenocarcinoma (PDAC) Growth In Vivo (2014) (0)
RNA interference approaches for treatment of HIV-1 infection (2015) (0)
Cellular Delivery of Ribozymes (2017) (0)
581. Exploring Potency of Small RNAs for HIV Latency Reactivation (2015) (0)
Use of Polymerase Chain Reaction to Detect the Expression of the MT70,000 Heat Shock Genes in Control or Heat Shock Leukemic Cells as Correlated to Their Heat Response1 (2006) (0)
Melamine Functionalized Copolymer for Sequence Specific siRNA Loading and Ligand-Driven Delivery (2018) (0)
437. Alternative Strategies To Deliver Multiple shRNAs in Order to Simultaneously Inhibit Multiple Targets (2005) (0)
[19]Ribozymes as therapeutic agents and tools for gene analysis (1996) (0)
Abstract 382: MTL-STING restores endogenous STING expression for improving efficacy of cancer therapeutics (2022) (0)
Enhanced Inhibition of HIV‐1 Replication in Macrophages by Antisense Oligonucleotides, Ribozymes and Acyclic Nucleoside Phosphonate Analogues Delivered in pH‐Sensitive Liposomes (2001) (0)
Truncation in CCND1 mRNA 3′ UTR Is Associated with An Aggressive Phenotype and Chemoresistance (2008) (0)
Publisher Correction: The current state and future directions of RNAi-based therapeutics (2019) (0)
Cord Blood Transplantation for Long Term Management or Possible Cure of HIV Infection (2012) (0)
Oligonucleotide Mediated Mutational Analysis of Recognition Sequence Effects on Lariat Formation During Messenger RNA Splicing in Yeast (1987) (0)
BAFF-R Aptamer/STAT3 siRNA Construct Selectively Downregulates STAT3 mRNA in BAFF-R Expressing Lymphomas in Vitro and in Vivo (2012) (0)
Nucleic acid aptamers (2017) (0)
998. The HIV-1 LTR-hsp70 Fusion Promoter Directs HIV-1 Inducible Expression of Anti-Rev siRNA along with HIV-1 Rev Transdominant Mutant RevM10 (2005) (0)
A Conditional Pol II mono-promoter drives HIV-inducible CRISPR mediated Cyclin T1 suppression and HIV inhibition. (2023) (0)
Abstract CN07-04: RNAi in the treatment and epigenetics of cancer (2010) (0)
Ribozymes as therapeutic agents and genetic tools (2002) (0)
Simple identification of mutant clones. (1999) (0)
Synthesis and use of an amphiphilic dendrimer for siRNA delivery into primary immune cells (2020) (0)
580. In Vivo Analyses of Aptamers and siRNA Therapeutics Against HIV-1 in Humanized Mouse Model (2015) (0)
A Non-Human Primate Model for Lentivirus-Mediated Anti-HIV RNAi Strategies. (2004) (0)
Preface and Overview (2006) (0)
722. Silencing of Transforming Growth Factor-β Receptor II by RNA Interference Suppresses Extracellular Matrix Production in Rat Hepatic Stellate Cells (2006) (0)
Abstract B225: Short activating RNA (saRNA) targeting C/EBPA significantly inhibits cell proliferation of undifferentiated cancer cells. (2013) (0)
Abstract A9: De novo sequencing of circulating microRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer (2012) (0)
The Experiment Was a Success: Celebrating a Milestone in MTNA's Existence. (2017) (0)
The Chemical Synthesis of DNA and Its Uses in Molecular Biology (1984) (0)
Inhibition of HIV‐1 transcription by a tunable chimeric tRNA(Ser)‐nucloelar localizing trans‐activation response element (TAR) decoy (2013) (0)
RNA Interference-Based Gene Therapy Strategies for the Treatment of HIV Infection (2015) (0)
Potential Molecular Targets for Anti-HIV RNAi Therapeutics (2011) (0)
BOOK REVIEW Regulation of Gene Expression by Small RNAs (2010) (0)
Short activating RNA (saRNA) targeting C/EBPA significantly inhibits cell proliferation of undifferentiated cancer cells (2015) (0)
De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer (2012) (0)
Oligonucleotide therapeutics : First Annual Meeting of the Oligonucleotide Therapeutics Society (2006) (0)
Silencing RNA-triggered Transcriptional Gene Phylogenetic Comparison of Small Minireviews : (2011) (0)
548. Cyclophilin A as a cellular target for gene therapy of HIV-1 (2004) (0)
PRINCIPLES OF RNAi TRIGGER EXPRESSION FOR GENE THERAPY (2014) (0)
Drugging transcription factors with small activating RNAs: A novel approach for enhancing bone marrow therapy for monogenic rare diseases (2023) (0)
Resurrecting as Sequence-Specif c Therapeutics (2016) (0)
142. Evolution of Cell-Specific RNA Aptamers Against Glioblastoma Cancer Stem Cells Via Live Cell-Based SELEX (2015) (0)
Identification of Amino Acids and Nucleotides Required for Interaction Between BAFF‐R and its RNA Aptamer (2015) (0)
RNA Interference Technology: RNAi applications in living animal systems (2005) (0)
Lentiviral Vector Delivery of RNAi for the Treatment of HIV‐1 Infection (2007) (0)
366. Negative Feedback Inhibition of HIV-1: A Novel HIV-1 LTR-hsp70 Fusion Promoter Directs HIV-1 Inducible siRNA Expression (2004) (0)
Mechanistic aspects and therapeutic applications of RNAi (2007) (0)
440. A Non-Human Primate Model for Lentivirus-Mediated Anti-HIV RNAi Strategies (2005) (0)
Oligonucleotide Therapeutics (2010) (0)
Current Advances in Self-Assembly RNAi Nanoparticles (2013) (0)
Ribozymes which the expression of the CCR5 receptor are able to inhibit (1999) (0)
Partial Purification andSomeProperties ofAl-Pyrroline-5- Carboxylate Reductase fromEscherichia coli (1977) (0)
90 Potentiation of T-cell mediated tumor killing via modulation of the fas/fasL pathway (2020) (0)
A Non-Human Primate Model To Study Anti-HIV Gene Therapy Strategies. (2005) (0)
Small activating RNA to CEBPA as a novel therapeutic approach to treat patients with liver cancer (2016) (0)
247 Dual function BAFF receptor aptamers inhibit ligand induced proliferation and deliver siRNAs to NHL cells (2010) (0)
Development and Optimization of Logic Gated Small Interfering RNAs for Operation Inside Mammalian Cells (2020) (0)
For inhibiting the expression of the CCR5 receptor capable ribozymes (1999) (0)
Cell Host & Microbe Previews CholesterolPavestheWayforTopicallyAppliedViricides (2009) (0)
Targeted ribozymes to study gene function in Drosophila. (1999) (0)
Abstract LB192: MTL-CEBPA in combination with pembrolizumab converts an immune desert to an inflamed TME in solid tumors resistant to checkpoint blockade (2023) (0)
549. Nonconserved Sequence Motifs outside the Catalytic Core Improve the Trans-Splicing Efficiency of Anti-HIV Hammerhead Ribozymes (2004) (0)
759. In Search of an Effective Target: In Vivo Approach Using HIV-1 Specific siRNA and Ribozyme Libraries (2006) (0)
FANAZymes: A new class of nucleic acid enzymes. (2022) (0)
Antiviral applications of RNAi. (2006) (0)
692. A Novel RNAi Trigger Design Retains Potent, Target Specific Activity Despite Emerging Mutations in the Target Site (2015) (0)
Targeting Strategies For Anti-hiv-1 Ribozymes: Chimeric trna Primer and Dimerization Signal Ribozymes (1993) (0)
Detecting blood clots with aptamers: A potentially lifesaving new tool in medicine (2023) (0)
Communication Enhancement During Planetary Entry (Abstract) (1968) (0)
Mammalian Transcriptional Gene Silencing by Small RNAs (2009) (0)
Involvement of Small Non‐Coding RNA in HIV‐1 Infection (2013) (0)
Redox Sensitive Metastable DNA Junctions for Multivalent Delivery of Therapeutics (2018) (0)
The Effect of Dicer Knockout on RNA Interference Using Various Dicer Substrate Small Interfering RNA (DsiRNA) Structures (2022) (0)
Corrigendum to "Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo". (2016) (0)
AIDS and Hematopoietic Transplantation: HIV Infection, AIDS, Lymphoma and Gene Therapy (2007) (0)
Short Hairpin RNA Causes the Methylation of Transforming Growth Factor- β Receptor II Promoter and Silencing of the Target Gene in Rat Hepatic Stellate Cells (2008) (0)
Stereopure oligo therapy for ALS. (2022) (0)
- Cell-Specific Aptamer-Functionalized RNAi: A New Prospect for Targeted siRNA Delivery (2013) (0)
743. Lentiviral Vector Gene Transfer in Monkeys: In Vivo. Detection of Gene Expression Longitudinally Using MicroPET and Optical Imaging (2005) (0)
Enhancing RNAi with Synthetic RNA Duplexes (2005) (0)
586. Dimerization Inhibition of HIV-1 RNA by 2’-Deoxy-2’-fluoro-beta-D-arabinose Nucleic Acid (2’-FANA) Modified Antisense Oligonucleotides Results in Potential Inhibition of Viral Expression (2016) (0)
Engineering and optimization of the miR-106b cluster for ectopic expression of multiplexed anti-HIV RNAs (2008) (0)
Systemic RNA interference (RNAi) therapeutics for the treatment of HIV-1 (2014) (0)
RNA Interference–Based Gene Therapy Strategies for the Treatment of HIV (2008) (0)
Ongoing Complete Remissions in ZUMA-1: A Phase 1-2 Multicenter Study of KTE-C19 (Anti-CD19 CAR T Cells) in Patients with Refractory Aggressive B Cell Non-Hodgkin Lymphoma (2016) (0)
Partial Purification and Some Properties of Al-Pyrroline-5- (0)
Front Cover: Advanced Cell Mapping Visualizations for Single Cell Functional Proteomics Enabling Patient Stratification (2020) (0)
Author Correction: The current state and future directions of RNAi-based therapeutics (2019) (0)
Retroviruses for Cancer Therapy (2014) (0)
436. shRNAs Target HIV-1 Vif Gene Coding for SOCS-Box Motif Prevent Virus Escape from RNA Interference-Mediated Inhibition (2005) (0)
Molecular Therapy's New Open-access Sibling (2012) (0)
Hematopoietic Cell Transplantation for Patients with Human Immunodeficiency Virus Infection (2009) (0)
Amplification de l'expression d'arn interferent (arni) et effets associes (2005) (0)
283. Targeted Delivery of C/EBPα-Small Activation RNA (saRNA) by RNA Aptamer Inhibits the Growth of Pancreatic Ductal Adenocarcinoma (PDAC) In Vivo (2015) (0)
The current state and future directions of RNAi-based therapeutics (2019) (0)
Parallel assessment of silencing potency of conventional siRNAs vs. Dicer substrate interfering RNAs (2010) (0)
Transduction of Macaque Hematopoietic Repopulating Cells with Lenti and Foamy Retroviral Vectors with MGMT Selection Cassettes To Evaluate AIDS Gene Therapy Strategies. (2006) (0)
Abstract 1508: MTL-CEBPA activates the transcription factor CEBPalpha leading to inhibition of hepatocellular cancer growth (2017) (0)
410. Multivalent siRNAs for Combinatorial HIV Gene Therapy (2004) (0)
LGIT In Vitro Latency Model in Primary and T Cell Lines to Test HIV-1 Reactivation Compounds. (2016) (0)
Use of Polymerase Chain Reaction to Detect the Expression of the MT 70 , 000 Heat Shock Genes in Control or Heat Shock Leukemic Cells as Correlated to Their Heat Response 1 (2006) (0)
Methods for producing molecules of RNAi in mammalian cells and therapeutic uses for such molecules (2003) (0)
AptaTRACE Elucidates RNA Sequence-StructureMotifs from Selection Trends in HT-SELEX Experiments Graphical Abstract Highlights (2016) (0)
Treating murine Hurler syndrome utilizing small-activating RNA following bone marrow transplant (2023) (0)
Methode d'identification de sites de liaison accessibles dans l'arn (2000) (0)
CHAPTER 12. Advances and Challenges of RNAi-Based Anti-HIV Therapeutics (2019) (0)
62. Aptamer-siRNA Conjugate Directed Transcriptional Gene Silencing in HIV-1 Infected T Cells (2015) (0)
Ribozymes. (1992) (0)
Twenty-five plus years of an RNA addiction (2015) (0)
Bifunctional siRNA Design Targeting Non-Hodgkin’s Lymphoma. (2007) (0)
siRNAs Against Cyclin D1/D2 Improves Cytotoxicity of Chemotherapy In Mantle Cell Lymphoma (2010) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With J. John Alta Loma Rossi?

J. John Alta Loma Rossi is affiliated with the following schools:

University of Connecticut
University of Texas Southwestern Medical Center